Literature DB >> 23139619

Newly developed autoimmune cholangitis without relapse of autoimmune pancreatitis after discontinuing prednisolone.

Ji Hun Kim1, Jae Hyuck Chang, Sung Min Nam, Mi Jeong Lee, Il Ho Maeng, Jin Young Park, Yun Sun Im, Tae Ho Kim, Chang Whan Kim, Sok Won Han.   

Abstract

A 57-year-old man presented with a 2-wk history of painless jaundice and weight loss. He had a large ill-defined enhancing mass-like lesion in the uncinate process of the pancreas with stricture of the distal common bile duct. Aspiration cytology of the pancreatic mass demonstrated inflammatory cells without evidence of malignancy. Total serum immunoglobulin G level was slightly elevated, but IgG4 level was normal. After the 2-wk 40 mg prednisolone trial, the patient's symptoms and bilirubin level improved significantly. A follow-up computed tomography (CT) scan showed a dramatic resolution of the pancreatic lesion. A low dose steroid was continued. After six months he self-discontinued prednisolone for 3 wk, and was presented with jaundice again. A CT scan showed newly developed intrahepatic biliary dilatation and marked concentric wall thickening of the common hepatic duct and the proximal common bile duct without pancreatic aggravation. The patient's IgG4 level was elevated to 2.51 g/L. Prednisolone was started again, after which his serum bilirubin level became normal and the thickening of the bile duct was resolved. This case suggests that autoimmune pancreatitis can progress to other organs that are not involved at the initial diagnosis, even with sustained pancreatic remission.

Entities:  

Keywords:  Autoimmune disease; Cholangitis; Pancreatitis; Prednisolone

Mesh:

Substances:

Year:  2012        PMID: 23139619      PMCID: PMC3491610          DOI: 10.3748/wjg.v18.i41.5990

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  13 in total

1.  Lymphoplasmacytic sclerosing pancreatitis is a pancreatic lesion of IgG4-related systemic disease.

Authors:  Terumi Kamisawa; Nobuaki Funata; Yukiko Hayashi
Journal:  Am J Surg Pathol       Date:  2004-08       Impact factor: 6.394

Review 2.  Autoimmune pancreatitis.

Authors:  Dmitry L Finkelberg; Dushyant Sahani; Vikram Deshpande; William R Brugge
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

3.  Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis.

Authors:  Raghuwansh P Sah; Suresh T Chari; Rahul Pannala; Aravind Sugumar; Jonathan E Clain; Michael J Levy; Randall K Pearson; Thomas C Smyrk; Bret T Petersen; Mark D Topazian; Naoki Takahashi; Michael B Farnell; Santhi S Vege
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

4.  Intrapancreatic common bile duct involvement of autoimmune pancreatitis: is it really IgG4-associated cholangitis?

Authors:  Do Hyun Park; Myung-Hwan Kim
Journal:  Gastroenterology       Date:  2008-06-11       Impact factor: 22.682

Review 5.  Management strategies for autoimmune pancreatitis.

Authors:  Terumi Kamisawa; Kensuke Takuma; Seiichi Hara; Taku Tabata; Sawako Kuruma; Yoshihiko Inaba; Rajesh Gopalakrishna; Naoto Egawa; Fumihide Itokawa; Takao Itoi
Journal:  Expert Opin Pharmacother       Date:  2011-06-28       Impact factor: 3.889

6.  [Clinical characteristics, recurrence features, and treatment outcomes of 55 patients with autoimmune pancreatitis].

Authors:  Soo Jung Park; Myung Hwan Kim; Sung Hoon Moon; Jeung Hye Han; Do Hyun Park; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee
Journal:  Korean J Gastroenterol       Date:  2008-10

Review 7.  Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease.

Authors:  Terumi Kamisawa; Atsutake Okamoto
Journal:  J Gastroenterol       Date:  2006-07       Impact factor: 7.527

8.  Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study.

Authors:  S-H Moon; M-H Kim; D H Park; C Y Hwang; S J Park; S S Lee; D W Seo; S K Lee
Journal:  Gut       Date:  2008-06-26       Impact factor: 23.059

9.  Standard steroid treatment for autoimmune pancreatitis.

Authors:  T Kamisawa; T Shimosegawa; K Okazaki; T Nishino; H Watanabe; A Kanno; F Okumura; T Nishikawa; K Kobayashi; T Ichiya; H Takatori; K Yamakita; K Kubota; H Hamano; K Okamura; K Hirano; T Ito; S B H Ko; M Omata
Journal:  Gut       Date:  2009-04-26       Impact factor: 23.059

10.  Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis.

Authors:  Neomal S Sandanayake; Nicholas I Church; Michael H Chapman; Gavin J Johnson; Dipok K Dhar; Zahir Amin; Maesha G Deheragoda; Marco Novelli; Alison Winstanley; Manuel Rodriguez-Justo; Adrian R W Hatfield; Stephen P Pereira; George J M Webster
Journal:  Clin Gastroenterol Hepatol       Date:  2009-04-01       Impact factor: 11.382

View more
  2 in total

1.  PRSS1_p.Leu81Met mutation results in autoimmune pancreatitis.

Authors:  Feng Gao; Yue-Ming Li; Guo-Lin Hong; Zhi-Feng Xu; Qi-Cai Liu; Qing-Liang He; Li-Qing Lin; Shao-Huang Weng
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

Review 2.  Framework for interpretation of trypsin-antitrypsin imbalance and genetic heterogeneity in pancreatitis.

Authors:  Kun Lin; Feng Gao; Qingquan Chen; Qicai Liu; Shu Chen
Journal:  Saudi J Gastroenterol       Date:  2015 Jul-Aug       Impact factor: 2.485

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.